- Report
- August 2024
- 100 Pages
Global
From €5640EUR$5,950USD£4,711GBP
- Report
- August 2024
- 175 Pages
Global
From €4739EUR$5,000USD£3,959GBP
- Report
- January 2025
- 130 Pages
Global
From €2843EUR$2,999USD£2,375GBP
- Report
- March 2025
- 180 Pages
Global
From €4265EUR$4,500USD£3,563GBP
- Report
- August 2024
- 85 Pages
United States
From €3317EUR$3,500USD£2,771GBP
- Report
- June 2023
- 115 Pages
Global
From €4265EUR$4,500USD£3,563GBP
- Report
- August 2023
- 217 Pages
Global
From €7109EUR$7,500USD£5,939GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1422EUR$1,500USD£1,188GBP
- Report
- February 2024
- 106 Pages
Global
From €4502EUR$4,750USD£3,761GBP
- Report
- September 2024
- 105 Pages
Global
From €3500EUR$3,956USD£3,026GBP
- Report
- April 2022
- 102 Pages
Global
From €1896EUR$2,000USD£1,584GBP
Alpha-galactosidase is a type of enzyme used to treat endocrine and metabolic disorders. It is used to treat Fabry disease, a rare genetic disorder that affects the body's ability to break down certain fats. Alpha-galactosidase helps break down these fats, allowing them to be eliminated from the body. It is also used to treat other metabolic disorders, such as Gaucher disease, which is caused by an enzyme deficiency. Alpha-galactosidase is available in both oral and injectable forms.
Alpha-galactosidase is a relatively new drug in the endocrine and metabolic disorders market. It is used to treat a variety of conditions, including Fabry disease, Gaucher disease, and other metabolic disorders. It is a promising treatment option for these conditions, as it can help reduce symptoms and improve quality of life.
Several companies are involved in the Alpha-galactosidase market, including Shire, Sanofi, and Genzyme. These companies produce and market the drug, as well as provide support and resources for patients. Show Less Read more